

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-33 - Cancelled.

34. (Currently Amended) A pharmaceutical compositions, wherein said pharmaceutical composition comprises ~~the ginseng fraction according to any one of claims 14, 17 and 25-33~~ CVT-E0002 and in combination with a pharmaceutically acceptable carrier.

35. (Currently Amended) ~~Use of a ginseng fraction according to any one claims 14, 17 and 25-33, alone or in combination with another medicament, in preparation of A method of preparing~~ a pharmaceutical composition suitable for treating a condition characterized by low immunity, wherein said method comprises adding a low immunity condition effective treating amount of CVT-E002 and, optionally, another medicament that is suitable for treating a condition characterized by low immunity in a low immunity condition effective treating amount with at least one pharmaceutically acceptable excipient to produce a pharmaceutical composition suitable for treating a condition characterized by low immunity.

36. (Currently Amended) ~~Use~~ The method of claim 35, wherein the condition is selected from the group consisting of common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

37. (Currently Amended) Use of a ginseng fraction according to any one of claims 14, 17 and 24-33 to stimulate A method of stimulating the production of IL-1, IL-16 and/or TNF- $\alpha$  in cells, wherein said method comprises administering a production stimulating effective amount of CVT-E002 to said cells.

38. (Currently Amended) Use of a ginseng fraction according to any one of claims 14, 17 and 24-33 to stimulate A method of stimulating the *in vitro* or *in vivo* production of immunoglobulins, wherein said method comprises administering an *in vitro* or *in vivo* production stimulating amount of CVT-E002.

39. (Currently Amended) Use of a ginseng fraction according to any one of claims 14, 17 and 25-33 to activate A method of activating B-lymphocyte proliferation and the resulting antibody production therefrom, wherein said method comprises administering a B-lymphocyte proliferating amount of CT-E002.


40. (Currently Amended) A method of treating a condition characterized by low immunity in a patient in need thereof, comprising administering to be patient a condition treating effective amount of a ginseng fraction according to any one of claims 14, 17 and 25-33 CVT-E002.

41. (Original) The method of claim 40, wherein the condition is selected from the group consisting of common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

Claims 42-50 Cancelled.

Respectfully submitted,

By

  
Robert B. Murray, Reg. No. 22,980

Attorney for Applicant

Rothwell, Figg, Ernst & Manbeck, P.C.

Suite 800, 1425 K Street, NW

Washington, D.C. 20005

Telephone: (202) 783-6040

Facsimile: (202) 783-6031

2968-171.amd